F
anconi anemia is a genetic disorder caused by loss of function of any of 14 genes in the FA pathway, a pathway coordinating cellular DNA damage repair mechanisms particularly involved in protection from DNA cross-linking agents. 2 Clinically, FA manifests with bone marrow failure and increased propensity to malignancy. Genetic complementation of the FA pathway has been shown to correct the hematopoietic defects in mouse models and in cases of somatic mosaicism arising from spontaneous reversion of the mutations in humans (natural gene therapy). However, a major obstacle to translation to human gene therapy is the low yield of autologous hematopoietic stem cell (HSC) harvests from FA patients and the difficulties in their in vitro culture. Induced pluripotent stem cells offer the possibility to generate unlimited numbers of patient-specific cells and provide, from this perspective, a promising alternative therapy for FA. But pluripotent stem cell gene therapies come with their own set of problems. Reprogramming and prolonged expansion of cells may induce genomic alterations. And genetic correction should not impose additional genotoxicity.
The authors of a previous study were successful in deriving FA patient iPS cells only after the genetic defect was corrected by lentiviral transfer of the FANCA gene in the fibroblasts before reprogramming 3 and not from uncorrected cells, which lead to the conclusion that restoration of the FA pathway is an absolute prerequisite for reprogramming. In contrast, in the present study, Müller and coworkers show that a defective FA pathway does not completely abolish reprogramming. The authors set to further investigate the reprogramming defect of FA cells and its mechanisms. They show that murine Fanca Ϫ/Ϫ and Fancc Ϫ/Ϫ fibroblasts have a higher incidence of dsDNA breaks-both pre-existing and induced during reprogramming-and exhibit increased reprogramming-induced senescence compared with wild-type (wt) fibroblasts (see figure) . They also show that reactive oxygen species generation during reprogramming contributes to chromosome breaks and that hypoxia has a more beneficial effect in boosting reprogramming of FA than wt cells, presumably by preventing oxidative damage. Genetic correction of murine Fanca Ϫ/Ϫ fibroblasts reduces senescence and restores the reprogramming efficiency to wt levels. Similarly, genetically corrected human FA cells exhibit enhanced reprogramming compared with uncorrected fibroblasts. Importantly, the present study suggests that corrected FA iPS cell lines are less likely to contain chromosomal aberrations. These findings taken together point to a model that links the reprogramming deficit to the deficient reprogramming-induced DNA damage repair, which may lead to elimination of cells with accumulated DNA damage through senescence or other mechanisms.
This study shows that reprogramming of FA cells before genetic correction is a viable option, and raises the question, "Which should come first?" The advantage of correcting first is not only the higher reprogramming efficiency but also the potentially enhanced genomic stability of the resulting iPS cells, a very important consideration for stem cell therapies. However, the possibilities for genetic manipulation of somatic cells are limited: somatic cells are generally poorly clonable and selection of cells with the desired genetic modification or elimination of those with potentially risky transgene insertions may not be For personal use only. 3 so it may be possible to correct and reprogram simultaneously and screen corrected iPS cell clones at the end of the process to exclude genotoxicity imposed by both the genetic modification and reprogramming at once. Which would be the preferred strategy? Further studies to address which strategy can yield iPS cells with adequate efficiency and quality together with anticipated advances in reprogramming and genetic modification methods will eventually inform the next steps toward translation to the clinic.
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Comment on Pabst et al, page 5367
Be quick, but don't hurry ----------------------------------------------------------------------------------------------------------------Elihu Estey UNIVERSITY OF WASHINGTON
In this issue of Blood, Pabst et al report that granulocyte-colony stimulating factor (G-CSF) "priming" improves event-free and overall survival (EFS and OS) only in those adults less than 60 years old given escalated doses of cytarabine (ara-C) for treatment of newly diagnosed acute myeloid leukemia (AML). 1 E fforts to improve the frequently unsatisfactory results after treatment of this disease typically entail other cytotoxins in combination with, or as replacements for, standard daunorubicin (or idarubicin) plus ara-C. Another approach emphasizes noncytotoxic drugs to sensitize ("prime") AML blasts to standard therapy. Use of CXCR4 inhibitors to detach marrow blasts from their protective stroma is a recent example, 2 but a much earlier example was G-CSF. Originally given before and/or during standard induction therapy to place more blasts into S-phase of the cell cycle where sensitivity to such therapy is thought greatest, G-CSF priming has had a checkered 20-year history. 3 A particularly noteworthy study (HOVON-SAKK AML-29) whose authors include some of those from the current study randomized 730 adults less than 60 years old with newly diagnosed AML to receive or not receive G-CSF beginning 1 day before, and continuing during, chemotherapy: cycle 1 ϭ idarubicin, ϩ ara-C at 200 mg/m2 daily ϫ7, cycle 2 ϭ amsacrine, ϩ ara-C at 1g/m2 twice daily ϫ12. 4 Although G-CSF generally reduced the risk of relapse, an improvement in EFS (hazard ratio [HR] 0.75, P ϭ .01) and OS (HR 0.75, P ϭ .02) occurred only in the 72% of patients with intermediate risk cytogenetics. Despite these results, G-CSF priming has not found widespread acceptance.
To Pabst et al's great credit a primary purpose of the current, and larger, study (HOVON-42) was to confirm the findings of AML-29, as well as to see if the OS benefit might be more widespread. HOVON-42 was initially conducted within the context of a randomization to either conventional dose ara-C, given as in AML-29, or escalated dose ara-C: cycle 1 ϭ 1g/m2 twice daily ϫ10, cycle 2 ϭ 2g/m2 twice daily days 1, 2, 4, and 6. Within each of these groups patients were randomized to ϩ/Ϫ G-CSF, given during each cycle's chemotherapy. Nine hundred seventeen patients were randomized to ϩ/Ϫ G-CSF with 709 receiving conventional dose and 207 escalated dose ara-C. Despite striking similarities between the conventional-dose ara-C arms of AML-29 and HOVON-42, the latter could not reproduce the decrease in relapse risk seen generally in the G-CSF arm of the former, nor the improvement in EFS and OS observed in the intermediate-risk cytogenetic group when given G-CSF (HRs 0.95 and 1.01, respectively, in HOVON-42). There was, however, the above-noted improvement in EFS (HR 0.59, P ϭ .003) and OS (HR 0.65, P ϭ .012), due primarily to less risk of relapse, in the escalated dose ara-C group given G-CSF.
Pabst and colleagues explicitly seek explanations for the discrepant results, but find none specifically related to the 2 studies that appear plausible. They clearly recognize the possibility that the improved EFS and OS in patients given escalated dose ara-C ϩ G-CSF in HOVON-42 will eventually prove to be a chance observation, even though they adjusted the above-noted P values to reflect the several tests of statistical significance they performed.
Therapeutic findings aside, Pabst et al's report is an important reminder of the limitations of even very well conducted randomized trials (phase 3) such as AML-29 and HOVON-42. There are several reasons why such trials may prove misleading. Most basically, as the authors imply, the results are statistics, not facts. Assume that among 100 new treatments for AML, 90 are truly not useful while 10 are truly useful; history suggests this is not unrealistic. 5 Further assume a phase 3 trial formulated to have a 5% false positive rate (ie, P ϭ .05) and a 20% false negative rate (ie, power ϭ 80%). Eight of the 10 truly useful treatments will be called useful as will 4 of the truly not useful treatments. Hence, 
